Contributor Page
Beeser Ramamoorthy LLP
 
Email  |  Articles
Contact Details
Tel: +1 647 4775513
Fax: +1 647 4775513
845 St. Clair Ave West, Suite 400
Toronto
Ontario
M6C 1C3
Canada
By Scott Beeser
On July 19, 20120 the European Court of Justice (ECJ) rendered it decision in Case C-130/11 dealing with the availability of Supplementary Protection Certificates (SPCs) for new uses.
By Scott Beeser
The applications involved Canadian Patent No. 2,372,576 and 2,487,054.
By Scott Beeser
On June 15, 2012, Justice Zinn issued Judgments in two prohibition proceedings between Sandoz and Fournier in respect of fenofibrate tablets and Canadian Patent Nos. 2,372,576 (Court File No. T-991-10) and 2,487,054 (Court File No. T-1184-10).
By Scott Beeser
The District Court for the Southern District of New York issued a decision that Sandoz/Momenta and Mylan/Natco infringed all of the asserted claims of Teva's glatiramer acetate patents.
By Scott Beeser
On June 18, 2012, the Federal Court of Canada issued a Judgment and Reasons for Judgment in a prohibition proceeding between Allergan and Apotex involving Allergan’s brimonidine + timolol combination product (COMBIGAN) and Canadian Patent No. 2,440,764.
By Scott Beeser
On June 15, 2012, the District Court for the District of New Jersey released its redacted opinion in litigation between Schering and Apotex involving mometasone furoate monohydrate (NASONEX) and US. Patent No. 6,127,353.
By Kavita Ramamoorthy
On June 14, 2012, the Supreme Court of Canada ("SCC") denied leave to hear an appeal involving section 8 of the Patented Medicines (Notice of Compliance) Regulations.
By Scott Beeser
On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).
By Kavita Ramamoorthy
On April 16, 2012, the U.S. Court of Appeals for the Federal Circuit (Cephalon et.al. v Mylan Pharmaceuticals et.al.) overturned a Delaware District Court's finding that U.S. Patent Nos. 7,387,793 and 7,544,372 were obvious.
By Scott Beeser
GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech's Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents.